Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. The stock has traded between $27.47 and $28.45 so far today. Choose from contactless Same Day Delivery, Drive Up and more. These are the marijuana stocks with the lowest 12-month trailing price-to-sales (P/S) ratio. We do not sell or share your information with anyone. By using this site you agree to the The President & CEO of Halozyme is Exercising Options, A Director at Halozyme (HALO) is Selling Shares, Bristol Myers' (BMY) Opdivo Wins EC Nod for Esophageal Cancer, Alexion's (ALXN) Ultomiris IV Formulation Gets EC Approval, Horizon (HZNP) and Halozyme Ink Deal for ENHANZE Technology, Roche (RHHBY) Gets FDA Nod for Influenza Drug Label Expansion, Novartis (NVS) Partners With Mesoblast for ARDS Cell Therapy, Gilead (GILD) Reports Positive Top-Line Data on HIV Candidate, Kodiak (KOD) Closes Enrollment in Phase IIb/III Wet AMD Study, Bristol Myers' (BMY) CAR T-Cell Therapy BLA Review Delayed, J&J (JNJ) Seeks Label Expansion of Darzalex Faspro Combination, Kodiak Sciences (KOD) Q3 Earnings Miss, KSI-301 in Focus, Puma (PBYI) Down 8% on Q3 Earnings Lag, Nerlynx Sales View Cut, Axsome's (AXSM) Q3 Earnings In Line, Pipeline Progresses, Editas' (EDIT) Earnings Rise Y/Y in Q3, EDIT-101 in Focus. Our goal for our members is to get our Alert’s first before the crowd. Delicious healthy ice cream. >> Sign Up Now to Get Name & Ticker Symbol of Next Triple-Digit Gainer <<, Join now to get the pre-market morning brief 100% free. Stock Ideas and Recommendations. The company raises outlook for the year anticipating higher royalties. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA. For a wide assortment of Halo Top visit today. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock +129.05% up in year-to-date price movement. December 2015: $0: Other Companies. Copyright © 2020 MarketWatch, Inc. All rights reserved. Log in to see them here or sign up to get started. Halozyme (HALO) reports better-than-expected third-quarter results. Craving Halo Top, but not sure where to get it? It focuses on novel oncology therapies that target the tumor microenvironment. Dollar Weakened Against Euro, Manufacturing Growth Also Remain Slow In U.S. Dollar Fell, Investors Waiting Fed Coming To A Definite Decision, U.S. To Mass Vaccinate In 2021, But 58% Are Willing. Click here now. Halozyme Therapeutics, Inc. (HALO) stock is trading at $27.84 as of 2:14 PM on Thursday, Sep 3, a decline of -$0.67, or -2.35% from the previous closing price of $28.51. Read our response here. The median projection represents growth adding up to 121.1% compared to sales growth for the corresponding quarter a year ago. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Subway will be the first brand ever to serve Halo Top's delicious ice cream in a hand-spun milkshake. Citizens Financial Group, Inc. (NYSE:CFG) Is Up 1.67% – Is It Capable of A Rally? What Is Going On With Sibanye Stillwater Limited (NYSE:SBSW)? Halozyme Therapeutics, Inc. has a market cap of $5.61 Billion and is expected to release its quarterly earnings report on Feb 22, 2021- Feb 26, 2021. There are currently no items in this Watchlist. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Halozyme Therapeutics, Inc. (NASDAQ:HALO) traded at $40.61 at close of the session on Tuesday, Dec 01, made an upward move of 3.86% on its previous day’s price. Request Access. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. The US dollar decline on Monday, November 30 as for the first time since August this year, the EUR/USD currency pair is trading at... On the health crisis front, investors are integrating the notable vaccines results of Pfizer (up 1.92 percent)/BioNTech (up 4.79 percent) and Moderna (up 16.35... Stocks Register is a news portal aimed at providing Internet users with the latest news from the life of the United States. Privacy Notice, and No, this is not a joke! 99 For HALO, shares are up 1.54% over the past week while the Zacks Medical - Biomedical and Genetics industry is up 0.58% over the same time period. Visit a quote page and your recently viewed tickers will be displayed here. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company. Company profile page for Eden Creamery LLC including stock price, company news, press releases, executives, board members, and contact information According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2020 is expected to hit $264.56 Million, or +35% up from figures reported last year. There have been 6 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. When investing in a tool like stocks, you need to focus on a long term: a few years or a few dozen years. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The company has a trailing 12-month PE ratio of 265.42. Sort by Featured. Shipping & Pickup. Long term indicators on average place the stock in the category of 100% Buy. HALO lost -$0.27 per share in the over the last 12 months. Shares short dropped in November from the previous month at 14.98 Million. Halo Top’s appeal is simple: a no-shame pint of low-sugar, high-protein ice cream with just 240 to 360 calories for the entire carton. Something went wrong while loading Watchlist. What Makes Halozyme Therapeutics (HALO) a Strong Momentum Stock: Buy Now? Regeneron (REGN), Sanofi Win EC Nod for Dupixent Label Expansion, Rhythm (RYTM) Up on FDA Approval of Weight Management Drug. 4.4 out of 5 stars with 23 reviews. Halo Top uses organic stevia, a plant-based sweetener, and erythritol, a sugar alcohol, to substitute sugar in their ice cream. Cannabis extraction company Halo Labs Inc. (NEO: HALO) (OTCQX:AGEEF) opted to acquire a debt of $18.44 million owed to Evolution Trustees Ltd., a … Your health & safety is our priority, and we're taking COVID-19 very seriously. "Halo Top is one of the most disruptive stories I've seen in my 10 years in the industry," says Wayne Wu, managing director and partner at VMG, an investor in food and beverage startups. 23. Based on estimates by 10 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Halozyme Therapeutics, Inc. (HALO) stock as a Hold, while 9 rate it as a Buy. Intraday Data provided by FACTSET and subject to terms of use. Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. Historical and current end-of-day data provided by FACTSET. The average price target for the stock over the next 12 months is $40.4, with the estimates having a low of $15 and a high of $60. The beta value is 1.83, while the average true range (ATR) is currently pointing at 1.81. This browser is no longer supported at MarketWatch. Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises Halozyme Therapeutics, Inc. HALO reported third-quarter 2020 earnings of 25 cents per share, beating the Zacks Consensus Estimate of … In terms of its 52-week price range, HALO has a high of $41.55 and a low of $12.71. 4.4 out of 5 stars with 23 reviews. Best-in-Class Portfolio Monitoring. Discovery to launch streaming channel in January, Georgia Republican reportedly flipped shares of anti-malware company dozens of times while serving on Senate’s cybersecurity subcommittee, We retired to Athens without speaking Greek — here’s how we got the easy travel and affordable life we wanted, Salesforce’s stock closes down more than 8% as Wall Street questions necessity of Slack purchase, FHFA Extends Foreclosure Moratorium to Jan. 31, Congressional leaders dismiss Trump’s threat to veto defense bill, CrowdStrike Stock Rallies as Profits and Revenue Blow Past Guidance, Trump rants against election results in 46-minute video, Halozyme Therapeutics started at buy with $39 stock price target at Benchmark, Halozyme Therapeutics stock price target raised to $24 from $17 at BMO Capital, Halozyme Therapeutics upgraded to outperform from market perform at BMO Capital, Halozyme's stock soars 13% in premarket trade after Bristol-Myers license deal, Halozyme to receive $105 mln upfront, potential royalties from Bristol-Myers as part of license deal, Halozyme enters license pact with Bristol-Myers, Halozyme started at market perform with $14 stock price target at BMO Capital, Halozyme Therapeutics started at buy with $12 stock price target at Deutsche Bank, Halozyme Therapeutics started at overweight with $27 stock price target at Barclays, Charting market cross currents, S&P 500 maintains 200-day average, Charting market cross currents, S&P 500 survives test of 200-day average, Charting a ‘rabbit from hat’ reversal, S&P 500 maintains the May range, Charting a bullish reversal, S&P 500 presses 20-day average ahead of Fed, Halozyme licenses Enhanze to Roche for new targets, Bull trend intact, U.S. benchmarks knife from well-defined support, Halozyme's stock soars after Bristol-Myers license deal, Halozyme shares fall after secondary share offering annoucned, S&P 500 whipsaws at the breakdown point, Nasdaq reclaims resistance, Roche's (RHHBY) Xolair Gets FDA Nod for Label Expansion.
2020 halo top stock